USANA Health Sciences (USNA)
(Delayed Data from NYSE)
$45.55 USD
-1.55 (-3.29%)
Updated May 3, 2024 04:00 PM ET
After-Market: $45.48 -0.07 (-0.15%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Balance Sheet
Fiscal Year End for USANA Health Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 330 | 288 | 240 | 312 | 235 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 61 | 67 | 98 | 90 | 69 |
Other Current Assets | 26 | 29 | 27 | 23 | 26 |
Total Current Assets | 418 | 384 | 365 | 425 | 329 |
Net Property & Equipment | 100 | 98 | 102 | 100 | 95 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 13 | 10 | 5 | 5 | 3 |
Intangibles | 47 | 50 | 48 | 48 | 46 |
Deposits & Other Assets | 55 | 55 | 58 | 62 | 43 |
Total Assets | 633 | 597 | 578 | 641 | 517 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 1 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 11 | 14 | 18 | 13 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 108 | 133 | 147 | 150 | 124 |
Total Current Liabilities | 119 | 144 | 161 | 168 | 136 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 4 | 8 | 12 | 10 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12 | 14 | 14 | 19 | 19 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 136 | 162 | 183 | 199 | 165 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 66 | 56 | 50 | 62 | 59 |
Retained Earnings | 445 | 392 | 345 | 383 | 306 |
Other Equity | -14 | -13 | 0 | -4 | -14 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 497 | 434 | 395 | 442 | 352 |
Total Liabilities & Shareholder's Equity | 633 | 597 | 578 | 641 | 517 |
Total Common Equity | 497 | 434 | 395 | 442 | 352 |
Shares Outstanding | 19.13 | 19.21 | 19.40 | 21.00 | 21.60 |
Book Value Per Share | 25.99 | 22.62 | 20.37 | 21.03 | 16.28 |
Fiscal Year End for USANA Health Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 330 | 307 | 300 | 295 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 61 | 60 | 62 | 64 |
Other Current Assets | NA | 26 | 23 | 26 | 36 |
Total Current Assets | NA | 418 | 390 | 388 | 396 |
Net Property & Equipment | NA | 100 | 95 | 96 | 97 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 13 | 15 | 16 | 8 |
Intangibles | NA | 47 | 46 | 47 | 49 |
Deposits & Other Assets | NA | 55 | 54 | 57 | 56 |
Total Assets | NA | 633 | 601 | 603 | 606 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 1 | 0 | 0 | 0 |
Accounts Payable | NA | 10 | 9 | 9 | 11 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 108 | 103 | 105 | 120 |
Total Current Liabilities | NA | 119 | 113 | 114 | 130 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 5 | 5 | 5 | 6 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 13 | 15 | 14 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 136 | 131 | 134 | 150 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 66 | 62 | 60 | 56 |
Retained Earnings | NA | 445 | 428 | 427 | 410 |
Other Equity | NA | -14 | -20 | -18 | -11 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 497 | 470 | 469 | 455 |
Total Liabilities & Shareholder's Equity | NA | 633 | 601 | 603 | 606 |
Total Common Equity | 0 | 497 | 470 | 469 | 455 |
Shares Outstanding | 19.24 | 19.13 | 19.30 | 19.30 | 19.30 |
Book Value Per Share | 0.00 | 25.99 | 24.37 | 24.29 | 23.59 |